fatty liver hepatic steatohepatitis
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Men and women * 18 yrs of age * Fasting plasma glucose *7.0 mmol/l * Liver biopsy in the last 6 months prior to inclusion or existing medical indication indication for liver biopsy * Written informed consent
Exclusion criteria
Exclusion criteria: * Exclusion criteria for MR (claustrophobia, pacemaker, metal implants, etc) * Exclusion criteria for liver biopsy (bleeding tendency, extended bile ducts etc) * ALT levels * 150 IU/ml * Creatinine levels * 120 IU/ml * Present excessive alcohol use defined as > 2 units/day * Present abuse of i.v. drugs (including methadon) * Infection with HIV or Hepatitis B/C * A psychiatric, addictive or any disorder that compromises the subjects ability to understand the study content and to give written informed consent for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameter is the level of hepatic FDG uptake in non-diabetic patients with biopsy-proven NASH and the level of hepatic FDG-uptake in non-diabetic patients with biopsy-proven non-inflammatory steatosis | — |
Secondary
| Measure | Time frame |
|---|---|
| FDG uptake levels will be studied in correlation with hepatic lipid content measured by 1H-MR-S, glucose tolerance status, determined by OGTT, transaminases and biochemical markers of inflammation. | — |
Countries
Netherlands
Outcome results
None listed